Recent Progress in Delivery of Therapeutic and Imaging Agents Utilizing Organic-Inorganic Hybrid Nanoparticles

Haque, Sheikh Tanzina; Chowdhury, Ezharul Hoque

doi:10.2174/1567201814666171120114034

Cited by 32 publications

(25 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, interests in the applications of various organic-inorganic hybrid nanoparticles (NPs) have risen tremendously. Hybrid NPs combine features of organic and inorganic building blocks and generate NPs with improved physicochemical properties, such as particle size and surface charge ( Haque and Chowdhury, 2018 ). Hybrid organic-inorganic NPs hold great promise in overcoming the pitfalls being faced by existing inorganic materials in the delivery of therapeutics and contrast agents ( Somasuntharam et al, 2016 ), such as unwanted interactions with serum proteins (particularly opsonins) and consequential removal from the circulation by macrophages of mononuclear phagocytic system, rapid renal clearance, prolonged body accumulation, and lack of targetability ( Zhou and Zhang, 2019 ).…”

Section: Organic-inorganic Hybrid Nanoparticlesmentioning

confidence: 99%

“…Table 2 lists recent studies that used inorganic NPs for cardiac therapy. In the organic-inorganic hybrid nanoparticles, the organic functional groups combine the unique properties of the inorganic counterparts to confer efficient utility for various in vivo biomedical and clinical applications ( Haque and Chowdhury, 2018 ). The use of hybrid nanoparticles for the slow release of drugs has been gaining great interest, particularly, to improve the selectivity and efficacy of the drugs by combining features of both organic and inorganic components in one nanoparticle system ( Table 3 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Nanoparticle-Mediated Drug Delivery for Treatment of Ischemic Heart Disease

Fan

Joshi

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

The regenerative capacity of an adult cardiac tissue is insufficient to repair the massive loss of heart tissue, particularly cardiomyocytes (CMs), following ischemia or other catastrophic myocardial injuries. The delivery methods of therapeutics agents, such as small molecules, growth factors, exosomes, cells, and engineered tissues have significantly advanced in medical science. Furthermore, with the controlled release characteristics, nanoparticle (NP) systems carrying drugs are promising in enhancing the cardioprotective potential of drugs in patients with cardiac ischemic events. NPs can provide sustained exposure precisely to the infarcted heart via direct intramyocardial injection or intravenous injection with active targets. In this review, we present the recent advances and challenges of different types of NPs loaded with agents for the repair of myocardial infarcted heart tissue.

show abstract

Section: Organic-inorganic Hybrid Nanoparticlesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Nanoparticle-Mediated Drug Delivery for Treatment of Ischemic Heart Disease

Fan

Joshi

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…Different organic materials including polymers, lipids, dendrimers, peptides attached to diverse inorganic nanoparticles like gold, mesoporous silica, magnetic iron oxide, carbon nanotubes, and quantum dots have been widely used for efficient drug delivery and imaging [133]. With continuing research in this area, the repertoire of organic-inorganic hybrid nanoparticles for mRNA delivery will be expanded.…”

Section: Nanotechnology Platforms For Mrna Deliverymentioning

confidence: 99%

Biomedical applications of mRNA nanomedicine

et al. 2018

View full text Add to dashboard Cite

As an attractive alternative to plasmid DNA, messenger RNA (mRNA) has recently emerged as a promising class of nucleic acid therapeutics for biomedical applications. Advances in addressing the inherent shortcomings of mRNA and in the development of nanoparticle-based delivery systems have prompted the development and clinical translation of mRNA-based medicines. In this review, we discuss the chemical modification strategies of mRNA to improve its stability, minimize immune responses, and enhance translational efficacy. We also highlight recent progress in nanoparticle-based mRNA delivery. Considerable attention is given to the increasingly widespread applications of mRNA nanomedicine in the biomedical fields of vaccination, protein-replacement therapy, gene editing, and cellular reprogramming and engineering.

show abstract

“…A significant amount of research has been invested into the development of potential novel inorganic therapeutics [1][2][3]. Since the platinum-based drug cis-platins serendipidous discovery, the development of primary and secondary structural analogues has increased exponentially; however, only some of have received FDA worldwide approval, i.e., carboplatin and oxaliplatin.…”

Section: Introductionmentioning

confidence: 99%

“…In 2009, an article by Gianferrara et al categorised metal anticancer compounds based on their mode of action, which could be divided into five different classes: [9] (1) the metal has a functional role, (2) the metal has a structural role, (3) the metal is a carrier for main ligands that are delivered in vivo, (4) the metal compound behaves as a catalyst in vivo, and (5) the metal compound is photoactive.…”

Section: Introductionmentioning

confidence: 99%

Structure-Property Relationships for a Series of Ruthenium(II) Polypyridyl Complexes Elucidated through Raman Spectroscopy

O’Neill¹,

Perdisatt²,

O’Connor³

2018

Journal of Spectroscopy

View full text Add to dashboard Cite

A series of ruthenium polypyridyl complexes were studied using Raman spectroscopy supported by UV/Vis absorption, luminescence spectroscopy, and luminescence lifetime determination by time-correlated single photon counting (TCSPC). The complexes were characterised to determine the influence of the variation of the conjugation across the main polypyridyl ligand. The systematic and sequential variation of the main polypyridyl ligand, 2-(4-formylphenyl)imidazo[4,5-f][1,10]phenanthroline (FPIP), 2-(4-cyanophenyl)imidazo[4,5-f][1,10]phenanthroline (CPIP), 2-(4-bromophenyl)imidazo[4,5-f][1,10]phenanthroline (BPIP), and 2-(4-nitrophenyl)imidazo[4,5-f][1,10]phenanthroline (NPIP) ligands, allowed the monitoring of very small changes in the ligands electronic nature. Complexes containing a systematic variation of the position (para, meta, and ortho) of the nitrile terminal group on the ligand (the para being 2-(4-cyanophenyl)imidazo[4,5-f][1,10]phenanthroline (p-CPIP), the meta 2-(3-cyanophenyl)imidazo[4,5-f][1,10]phenanthroline (m-CPIP) and 2-(2-cyanophenyl)imidazo[4,5-f][1,10]phenanthroline (o-CPIP)) were also characterised. Absorption, emission characteristics, and luminescence yields were calculated and correlated with structural variation. It was found that both the electronic changes in the aforementioned ligands showed very small spectral changes with an accompanying complex relationship when examined with traditional electronic methods. Stokes shift and Raman spectroscopy were then employed as a means to directly gauge the effect of polypyridyl ligand change on the conjugation and vibrational characteristics of the complexes. Vibrational coherence as measured as a function of the shifted frequency of the imizodale bridge was shown to accurately describe the electronic coherence and hence vibrational cooperation from the ruthenium centre to the main polypyridyl ligand. The well-defined trends established and elucidated though Raman spectroscopy show that the variation of the polypyridyl ligand can be monitored and tailored. This allows for a greater understanding of the electronic and excited state characteristics of the ruthenium systems when traditional electronic spectroscopy lacks the sensitivity.

show abstract

Recent Progress in Delivery of Therapeutic and Imaging Agents Utilizing Organic-Inorganic Hybrid Nanoparticles

Abstract: We have thus highlighted here the progress made so far in utilizing different organicinorganic hybrid nanoparticles for in vivo delivery of anti-cancer drugs, siRNA, genes and imaging agents.

Cited by 32 publications

References 0 publications

Nanoparticle-Mediated Drug Delivery for Treatment of Ischemic Heart Disease

Nanoparticle-Mediated Drug Delivery for Treatment of Ischemic Heart Disease

Biomedical applications of mRNA nanomedicine

Structure-Property Relationships for a Series of Ruthenium(II) Polypyridyl Complexes Elucidated through Raman Spectroscopy

Contact Info

Product

Resources

About